期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 32, 期 9, 页码 933-937出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2022.2113873
关键词
Amenamevir; antiviral; helicase-primase; herpes simplex virus; HN0037; HSV-1; HSV-2; IM-250; pritelivir
Helicase-primase is an interesting target for therapy of herpes simplex virus infections. Multiple drug candidates have been developed and approved. This article describes the patent portfolio of helicase-primase inhibitors from Phaeno Therapeutics and proposes the structure of their drug candidate HN0037.
Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and with pritelivir's granted breakthrough therapy designation for the treatment of acyclovir-resistant HSV infections in immunocompromised patients, the target has sparked interest for me-too approaches. We describe the opportunities and limitations of the helicase-primase inhibitor patent portfolio from Phaeno Therapeutics and propose the structure of their drug candidate HN0037, which has been in-licensed from Medshine Discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据